[Present evaluation of hansenian treatment by association of chemotherapy and immunostimulation (author's transl)].
I.--Treatment with BCG and DDS in lepromatous or borderline patients. II.--Value of BCG added to a prior and long-continued treatment with DDS or rifamipicine. III.--Value of various immunostimulants given previously to a treatment with BCG and chemotherapy. IV.--Value of lysate of Neisseria perflava as an immunostimulant associated with DDS in an initial treatment of lepromatous and borderline patients. V.--Results of a seventeen months treatment of lepromatous and borderline patients with a lysate of Neisseria perflava associated with DDS. The various therapeutic trials reported in these 5 papers demonstrate that hansenian nevritis conventionnally treated may show improvement when an immunostimulant (BCG or bacterial lysate or levamisole) is given either previously or in association with DDS or rifampicine or after such a treatment. It has still been observed that two immunostimulants given simultaneously have no good effect and that this association must be discarded.
D000293:Adolescent; D000328:Adult; D001500:BCG Vaccine / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007918:Leprosy / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D007978:Levamisole / Q000627:therapeutic use; D008297:Male; D009343:Neisseria / Q000276:immunology; D012293:Rifampin / Q000627:therapeutic use
D001500:BCG Vaccine; D007978:Levamisole; D003622:Dapsone; D012293:Rifampin
Bilan actuel du traitement de la lépre par chimiothérapie et immunostimulation associées